search
Found 90 results for Oncology

Webinars

button
button
03 Nov 23
button
31 Oct 23
button

Videos

03 Jan

Gyankosh

Recent Updates in management of HER2+ Advanced breast cancer 
It’s a Video by Dr. Ramavath talking on recent updates in management of HER2+ Advanced...

Gyankosh

Recent Updates in management of HER2+ Advanced breast cancer 
It’s a Video by Dr. Ramavath talking on recent updates in management of HER2+ Advanced...

button
03 Jan

Gyankosh

Recent Updates in management of HER2+ Advanced breast cancer 
It’s a Video by Dr. Ramavath talking on recent updates in management of HER2+ Advanced...

button
27 Dec

Gyankosh

It’s a Video by Dr. Neeraj Jain talking on Mangament of chemotherapy induced Anemia

Gyankosh

It’s a Video by Dr. Neeraj Jain talking on Mangament of chemotherapy induced Anemia

button
27 Dec

Gyankosh

It’s a Video by Dr. Neeraj Jain talking on Mangament of chemotherapy induced Anemia

button
27 Nov

Gyankosh

It’s a Video by Dr.Dinky talking on recent update in Treatment selection and sequencing in first line and beyond

Gyankosh

It’s a Video by Dr.Dinky talking on recent update in Treatment selection and sequencing in first line and beyond

button
27 Nov

Gyankosh

It’s a Video by Dr.Dinky talking on recent update in Treatment selection and sequencing in first line and beyond

button

Courses

No results found.

Medshorts

2Min Read
26 Feb

Trifluridine/tipiracil shows survival benefits in patients with metastatic gastric/gastroesophageal junction cancer

A recent study found that trifluridine/tipiracil shows survival and functioning benefits in patients with metastatic gastric/gastroesophageal junction cancer in later lines of therapy. This study was published in the Journal of cancer research and clinical oncology.

The TAGS trial was a phase 3, randomized study that included 507 patients with metastatic gastric/gastroesophageal junction cancer and ≥ 2 prior chemotherapies. The participants were categorized into the following overlapping subgroups: ramucirumab ± other agents (n = 169), no ramucirumab (n = 338), paclitaxel but no ramucirumab (n = 136), ramucirumab + paclitaxel in combination or sequentially (n = 154). Other subgroups included neither paclitaxel nor ramucirumab (n = 202), irinotecan (n = 281), and no irinotecan (n = 226). Overall and progression-free survival (PFS), safety, and time to Eastern Cooperative Oncology Group performance status (ECOG PS) ≥ 2 were assessed.

Median overall survival across subgroups was found to be 4.6-6.1 versus 3.0-3.8 months while the median PFS was 1.9-2.3 versus 1.7-1.8 months. Similarly, the median time to ECOG PS ≥ 2 was 4.0-4.7 versus 1.9-2.5 months. Median overall and progression-free survival was longer in trifluridine/tipiracil-randomized patients who did not receive ramucirumab, paclitaxel and ramucirumab, or irinotecan. The safety profile for the interventional drug remained consistent across subgroups.

Thus, it can be concluded that trifluridine/tipiracil may show overall and progression-free survival as well as functioning benefits in patients with metastatic gastric/gastroesophageal junction cancer in later lines.

 

Trifluridine/tipiracil shows survival benefits in patients with metastatic gastric/gastroesophageal junction cancer

A recent study found that trifluridine/tipiracil shows survival and functioning benefits in patients with metastatic gastric/gastroesophageal junction cancer in later lines of therapy. This study was published in the Journal of cancer research and clinical oncology.

The TAGS trial was a phase 3, randomized study that included 507 patients with metastatic gastric/gastroesophageal junction cancer and ≥ 2 prior chemotherapies. The participants were categorized into the following overlapping subgroups: ramucirumab ± other agents (n = 169), no ramucirumab (n = 338), paclitaxel but no ramucirumab (n = 136), ramucirumab + paclitaxel in combination or sequentially (n = 154). Other subgroups included neither paclitaxel nor ramucirumab (n = 202), irinotecan (n = 281), and no irinotecan (n = 226). Overall and progression-free survival (PFS), safety, and time to Eastern Cooperative Oncology Group performance status (ECOG PS) ≥ 2 were assessed.

Median overall survival across subgroups was found to be 4.6-6.1 versus 3.0-3.8 months while the median PFS was 1.9-2.3 versus 1.7-1.8 months. Similarly, the median time to ECOG PS ≥ 2 was 4.0-4.7 versus 1.9-2.5 months. Median overall and progression-free survival was longer in trifluridine/tipiracil-randomized patients who did not receive ramucirumab, paclitaxel and ramucirumab, or irinotecan. The safety profile for the interventional drug remained consistent across subgroups.

Thus, it can be concluded that trifluridine/tipiracil may show overall and progression-free survival as well as functioning benefits in patients with metastatic gastric/gastroesophageal junction cancer in later lines.

 

button
2Min Read
26 Feb

Trifluridine/tipiracil shows survival benefits in patients with metastatic gastric/gastroesophageal junction cancer

A recent study found that trifluridine/tipiracil shows survival and functioning benefits in patients with metastatic gastric/gastroesophageal junction cancer in later lines of therapy. This study was published in the Journal of cancer research and clinical oncology.

The TAGS trial was a phase 3, randomized study that included 507 patients with metastatic gastric/gastroesophageal junction cancer and ≥ 2 prior chemotherapies. The participants were categorized into the following overlapping subgroups: ramucirumab ± other agents (n = 169), no ramucirumab (n = 338), paclitaxel but no ramucirumab (n = 136), ramucirumab + paclitaxel in combination or sequentially (n = 154). Other subgroups included neither paclitaxel nor ramucirumab (n = 202), irinotecan (n = 281), and no irinotecan (n = 226). Overall and progression-free survival (PFS), safety, and time to Eastern Cooperative Oncology Group performance status (ECOG PS) ≥ 2 were assessed.

Median overall survival across subgroups was found to be 4.6-6.1 versus 3.0-3.8 months while the median PFS was 1.9-2.3 versus 1.7-1.8 months. Similarly, the median time to ECOG PS ≥ 2 was 4.0-4.7 versus 1.9-2.5 months. Median overall and progression-free survival was longer in trifluridine/tipiracil-randomized patients who did not receive ramucirumab, paclitaxel and ramucirumab, or irinotecan. The safety profile for the interventional drug remained consistent across subgroups.

Thus, it can be concluded that trifluridine/tipiracil may show overall and progression-free survival as well as functioning benefits in patients with metastatic gastric/gastroesophageal junction cancer in later lines.

 

button
2Min Read
21 Feb

Lenvatinib plus pembrolizumab shows improved efficacy and overall survival in patients with advanced renal cell carcinoma

A recent study suggests that lenvatinib plus pembrolizumab shows improved efficacy and overall survival (OS) in specific subgroups of patients with advanced renal cell carcinoma(RCC). This study was published in the journal, European Urology Oncology.

The CLEAR trial was a phase 3, open-label, multicenter, randomized study that included 1069 patients who were randomized in a 1:1:1 ratio. The participants received either 20mg orally once a day of lenvatinib plus 200mg pembrolizumab intravenously once every 3 weeks, lenvatinib plus everolimus, or 50 mg sunitinib taken orally once daily for a period of 4 weeks and subsequently no treatment for 2 weeks. The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk subgroup analyzed progression-free survival, duration of response and objective response rate (ORR).

It was found that the patients administered with lenvatinib plus pembrolizumab with a confirmed complete response or >75% target-lesion reduction by 6 months showed an OS of ≥91.7% at 24 months. Compared to sunitinib, lenvatinib plus pembrolizumab showed longer median progression-free survival and a higher ORR. Based on the above results, it can be concluded that lenvatinib plus pembrolizumab may provide improved efficacy and better survival than sunitinib in patients with advanced RCC.

Lenvatinib plus pembrolizumab shows improved efficacy and overall survival in patients with advanced renal cell carcinoma

A recent study suggests that lenvatinib plus pembrolizumab shows improved efficacy and overall survival (OS) in specific subgroups of patients with advanced renal cell carcinoma(RCC). This study was published in the journal, European Urology Oncology.

The CLEAR trial was a phase 3, open-label, multicenter, randomized study that included 1069 patients who were randomized in a 1:1:1 ratio. The participants received either 20mg orally once a day of lenvatinib plus 200mg pembrolizumab intravenously once every 3 weeks, lenvatinib plus everolimus, or 50 mg sunitinib taken orally once daily for a period of 4 weeks and subsequently no treatment for 2 weeks. The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk subgroup analyzed progression-free survival, duration of response and objective response rate (ORR).

It was found that the patients administered with lenvatinib plus pembrolizumab with a confirmed complete response or >75% target-lesion reduction by 6 months showed an OS of ≥91.7% at 24 months. Compared to sunitinib, lenvatinib plus pembrolizumab showed longer median progression-free survival and a higher ORR. Based on the above results, it can be concluded that lenvatinib plus pembrolizumab may provide improved efficacy and better survival than sunitinib in patients with advanced RCC.

button
2Min Read
21 Feb

Lenvatinib plus pembrolizumab shows improved efficacy and overall survival in patients with advanced renal cell carcinoma

A recent study suggests that lenvatinib plus pembrolizumab shows improved efficacy and overall survival (OS) in specific subgroups of patients with advanced renal cell carcinoma(RCC). This study was published in the journal, European Urology Oncology.

The CLEAR trial was a phase 3, open-label, multicenter, randomized study that included 1069 patients who were randomized in a 1:1:1 ratio. The participants received either 20mg orally once a day of lenvatinib plus 200mg pembrolizumab intravenously once every 3 weeks, lenvatinib plus everolimus, or 50 mg sunitinib taken orally once daily for a period of 4 weeks and subsequently no treatment for 2 weeks. The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk subgroup analyzed progression-free survival, duration of response and objective response rate (ORR).

It was found that the patients administered with lenvatinib plus pembrolizumab with a confirmed complete response or >75% target-lesion reduction by 6 months showed an OS of ≥91.7% at 24 months. Compared to sunitinib, lenvatinib plus pembrolizumab showed longer median progression-free survival and a higher ORR. Based on the above results, it can be concluded that lenvatinib plus pembrolizumab may provide improved efficacy and better survival than sunitinib in patients with advanced RCC.

button
2Min Read
20 Feb

Improved respiratory function following surgery-based respiratory function exercise in elderly lung cancer patients

According to a recent study, it was found that enhanced recovery after surgery-based respiratory function exercise was seen in elderly patients with lung cancer. The results of this study were published in the journal, Alternative therapies in health and medicine.

This study included 109 elderly lung cancer patients, who were randomly assigned to either the control group (n=52), who received conventional care or the research group (n=57), who received enhanced recovery after surgery-based respiratory function exercise along with conventional care. Parameters such as respiratory function, functional capacity, incidence of pulmonary complications, and quality of life were studied before and after the intervention.

It was seen that the research group exhibited improved Forced Expiratory Volume in the first second, Forced Expiratory Volume in the first second/Forced Vital Capacity, and Forced Vital Capacity when compared to the control group (P < .05). This group also showed higher Barthel indices, indicating better functional capacity and lower St George's Respiratory Questionnaire scores, signifying better quality of life. The incidence of pulmonary complications was also found to be lower in the research group.

Based on the above findings, it may be concluded that respiratory function can be improved following surgery-based respiratory function exercise and can promote postoperative functional recovery, enhance the quality of life, and reduce pulmonary complications in elderly patients with lung cancer.

Improved respiratory function following surgery-based respiratory function exercise in elderly lung cancer patients

According to a recent study, it was found that enhanced recovery after surgery-based respiratory function exercise was seen in elderly patients with lung cancer. The results of this study were published in the journal, Alternative therapies in health and medicine.

This study included 109 elderly lung cancer patients, who were randomly assigned to either the control group (n=52), who received conventional care or the research group (n=57), who received enhanced recovery after surgery-based respiratory function exercise along with conventional care. Parameters such as respiratory function, functional capacity, incidence of pulmonary complications, and quality of life were studied before and after the intervention.

It was seen that the research group exhibited improved Forced Expiratory Volume in the first second, Forced Expiratory Volume in the first second/Forced Vital Capacity, and Forced Vital Capacity when compared to the control group (P < .05). This group also showed higher Barthel indices, indicating better functional capacity and lower St George's Respiratory Questionnaire scores, signifying better quality of life. The incidence of pulmonary complications was also found to be lower in the research group.

Based on the above findings, it may be concluded that respiratory function can be improved following surgery-based respiratory function exercise and can promote postoperative functional recovery, enhance the quality of life, and reduce pulmonary complications in elderly patients with lung cancer.

button
2Min Read
20 Feb

Improved respiratory function following surgery-based respiratory function exercise in elderly lung cancer patients

According to a recent study, it was found that enhanced recovery after surgery-based respiratory function exercise was seen in elderly patients with lung cancer. The results of this study were published in the journal, Alternative therapies in health and medicine.

This study included 109 elderly lung cancer patients, who were randomly assigned to either the control group (n=52), who received conventional care or the research group (n=57), who received enhanced recovery after surgery-based respiratory function exercise along with conventional care. Parameters such as respiratory function, functional capacity, incidence of pulmonary complications, and quality of life were studied before and after the intervention.

It was seen that the research group exhibited improved Forced Expiratory Volume in the first second, Forced Expiratory Volume in the first second/Forced Vital Capacity, and Forced Vital Capacity when compared to the control group (P < .05). This group also showed higher Barthel indices, indicating better functional capacity and lower St George's Respiratory Questionnaire scores, signifying better quality of life. The incidence of pulmonary complications was also found to be lower in the research group.

Based on the above findings, it may be concluded that respiratory function can be improved following surgery-based respiratory function exercise and can promote postoperative functional recovery, enhance the quality of life, and reduce pulmonary complications in elderly patients with lung cancer.

button